Recurrent Atrial Fibrillation Market Research Report with Industry Forecast and Outlook 2027
Research Reports
Jan 20, 2021
Market Size – USD 9.51 billion in 2019, Market Growth – CAGR of 13.2%, Market Trends – Advancements in device technology.
The increasing incidence of recurrent atrial fibrillation is majorly associated with recurrent paroxysmal atrial fibrillation patients, with the occurrence of a family history of AFib, high blood pressure, sleep apnea, overuse of stimulants, alcohol consumption, obesity, thyroid disorders, diabetes, lung disease, severe infections, and stress.
Factors driving this market include augmenting incidence rate of recurrent atrial fibrillation, new product launches for effective treatment of recurrent events, and improved reimbursement scenarios for recurrent AFib treatment drugs along with technological advancements are expected to become the most common growth factors globally in the coming years. Moreover, healthcare experts from the University of Pennsylvania have estimated that patients admitted to intensive care units for COVID-19 treatment are more likely to suffer from arrhythmia and atrial fibrillation. This would be alarming for cardiac patients and would lead to increased sales of atrial fibrillation associated drugs.
Browse the full report description @ https://www.emergenresearch.com/industry-report/recurrent-atrial-fibrillation-market
In January 2019, Abbott announced the acceptance of the TactiCath Touch Force Ablation Catheter by the FDA. Such winning tactics of leading companies in the market for atrial fibrillation products are often adopted by national and local companies.
The prevalence of AFib ranges between 2.7 million and 6.1 million in the U.S. alone and is estimated to reach 12.1 million by the year 2030, according to the statistics of the Center for Disease Control. Similar incidence rates are observed in other regions as well, indicating potential growth in the target industry.
Recently, in December 2019, the opening generic version of the blood thinner Eliquis received approval by the U.S. FDA. The drug is anticipated to provide quality treatment alternatives at affordable prices, especially for recurrent AFib patients, by reducing the risk of recurrence.
The device type product segment is estimated to reach USD 5.88 billion by the year 2027 at a CAGR of 14.0% during the forecast period.
Electrophysiology can estimate the electrical activity of the heart while the catheter ablation technique is used to treat arrhythmia of specific types. Electrophysiology is regarded as the most effective method for recurrent episodes of atrial fibrillation after drugs remain ineffective to the patient’s body.
Atrial fibrillation diagnosis includes screening as regular care in elderly patients and patients with other risk factors. Diagnostic testing also includes an ECG or EKG heart’s electrical activity. The presence of advanced software based ECG monitoring devices would improve the quality of treatment for recurrent atrial fibrillation patients.
Regional Scope- North America; Europe; Asia Pacific; Central & South America; MEA
For More Details Get FREE Sample Pages of this Research Report@ https://www.emergenresearch.com/request-sample-form/71
Key participants contributing significant market shares in the industry growth includes Johnson & Johnson, Medtronic Plc, Abbott Laboratories, Microport Scientific Corporation, Atricure Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Siemens AG, Koninklijke Philips N.V., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and GlaxoSmithKline.
Product Outlook (Revenue, USD Billion; 2017-2027)
Device
Surgical Devices
Maze Surgery
Catheter Ablation
Radiofrequency Catheter Ablation
Conventional RF Ablation Catheters
Irrigated-tip RF Ablation Catheters
Cryoablation
Microwave Based Catheter Ablation
Laser Based Catheter Ablation
Navigational Advanced Mapping Accessories
Non-Surgical Devices
Electric Cardioversion
EP Ablation Catheters
EP Diagnostic Catheter
Conventional Diagnostic Catheters
Fixed Diagnostic Catheters
Steerable Diagnostic Catheters
Advanced Diagnostic Catheters
Mapping and Recording Systems
Cardiac Monitors or Loop Recorders
Access Devices
Left Atrial Appendage and Closure Devices
Intracardiac Echocardiography (ICE) Systems
Drugs
Dabigatran (Pradaxa)
Rivaroxaban (Xarelto)
Apixaban (Eliquis)
Edoxaban (Savaysa)
Warfarin (Coumadin)
Others
Application Outlook (Revenue, USD Billion; 2017-2027)
EP Ablation
Diagnostic
Surgical Cardiac
End Users Outlook (Revenue, USD Billion; 2017-2027)
Hospitals
Cardiac Centers
Ambulatory Care Centers
Helping you establish a strong foothold in the industry
The Recurrent Atrial Fibrillation report highlights set of information related to pricing and the category of customers who are more than willing to pay for certain products and services. The information on opportunities as well as product features, determine which offerings or benefits command sale and identify the communications channels used by the market leaders to create premium positioning strategies as well as attract broadest share.
Browse the full report description @ https://www.emergenresearch.com/industry-report/recurrent-atrial-fibrillation-market
The research provides answers to the following key questions:
What is the estimated size of the Recurrent Atrial Fibrillation market for the forecast period, 2020 – 2027? What will be the growth rate of the industry during the estimated period?
What are the prominent driving forces likely to impact the progress of the industry across different regions?
Who are the major market players occupying a strong foothold in the Recurrent Atrial Fibrillation market? What are the winning strategies adopted by them to stay ahead in the competition?
What are the potential opportunities for the Recurrent Atrial Fibrillation market for the forecast period, 2020 – 2027?
What are the key trends expected to shape the development of the industry over the coming years?
What are the key restraints and challenges likely to hinder the growth of the Recurrent Atrial Fibrillation market worldwide?
Thank you for reading our report. For further information or queries about the report or customization options, please get in touch with us. We will ensure your report is tailored according to your requirements.
Related Reports:
Signal Intelligence (SIGINT) Market to Reach USD 18.28 Billion By 2027 | Emergen Research
Sodium Dichromate Market To Be Worth USD 1,242.4 Million by 2027| Emergen Research
Industrial Microbiology Market To Be Worth USD 17.71 Billion by 2027| Emergen Research
Surgical Instrument Tracking Systems Market To Reach USD 431.6 Million by 2027| Emergen Research
Medical Lighting Technologies Market Size To Be Worth USD 2.99 Billion by 2027 | Emergen Research
Tags:
, Reportedtimes, iCN Internal Distribution, Research Newswire, English
YOU MAY ALSO LIKE
Market Analysis and Trends of Finger Size…
Market Size – USD 9.51 billion in 2019, Market Growth – CAGR of 13.2%, Market Trends – Advancements in device technology. The increasing incidence of…
read more
All-in-One Video Conferencing Solutions Market Research Report…
Market Size – USD 9.51 billion in 2019, Market Growth – CAGR of 13.2%, Market Trends – Advancements in device technology. The increasing incidence of…
read more
2025 Automotive Electric Ceiling Display Panel Market…
Market Size – USD 9.51 billion in 2019, Market Growth – CAGR of 13.2%, Market Trends – Advancements in device technology. The increasing incidence of…
read more